European Journal of Cardiovascular Medicine

Breast cancer is the most common cancer amongst women with no regional variation and the second most cancer worldwide. Stromal contribution to progression of cancer will identify specific signals which promotes growth, differentiation, invasion and ectopic survival of tumour cells.

Stromal cells in breast carcinoma express CD10 which can cleave the matrix and help tumour invasion and metastasis.Core needle biopsy is the method of choice for pre operative assessment of breast lump.  Stroma of the tumour can contain more prognostic information than the epithelial component. Stromal cells in breast carcinoma may express CD10 which can cleave the matrix and help in identifying tumour invasion and metastasis.

This study is aprospective study which is conducted at the Histopathology laboratory, MGM Medical College, Navi Mumbai (July 2022- January 2024). After obtaining the surgical (mastectomy) specimen, H and E stainedsections will beprepared and histopathological (HPE) findings will be noted for histological grade and lympho-vascular invasion including final modified SBR score. Study group

comprised forty (40) cases of breast carcinoma diagnosed on core needle biopsy. Core needle biopsy will be performed on patients using 14-gauge needle of length 3 inches, under full aseptic precautions, using local anaesthesia. Tissue from core needle biopsy will be processed by fixing in 10% neutral buffered formalin overnight. Paraffin blocks will be prepared, and subsequently six slides will be cut from each.  Staining will be done with haematoxylin and eosin.

Ethical Aspect: The study was approved by Institutional Ethical Committee on 24/04/2023. Written informed consent was obtained for participation in the study and use of the patient data for research and educational purposes.

The present study included a sample of 30 patients, 29 female patients and 1 male patient diagnosed as infiltrating ductal carcinoma of breast fulfilling the inclusion criteria.CD10 was strong positive in 19 cases and weak positive in 8 cases in the malignant breast cases and 3 cases with negative results.

Table 1: Histopathological grade wise distribution of CD10 Positivity

Table 2: Comparison of CD10 expression with histological subtypes of Invasive Ductal Carcinoma

Comparison of CD10 expression with histological subtypes of Invasive Ductal Carcinoma

(IDC Mucin- IDC with mucinous differentiation, IDC with papillary differentiation, Colloid carcinoma, IDC- Not specific type)

We had studied CD 10 stromal expression of 30 breast carcinoma patients who had undergone Modified radical mastectomy.Comparison of the CD10 expression with age, showed extremes of age showing weak positivity. The reproductive age group showed maximum association with positivity for CD10 expression.Sayantan H Jana et al (2014) observed that comparison of age with CD10 positivity was not statistically significant.

In our study maximum number of patients were of IDC NST subtype and 23 out of the 30 IDC NST showed positive immunoreactivity with CD 10.Fereshteh Mohammadizadeh et al had 40 out of 44 patients with IDC NOS similar to our present study.

In our study, 8 out of the 30 patients (23%) showed grade 3 positive immunoreactivity with CD 10 expression. Keiichi Iwaya et al had 47 out of 110 patients belonging to histopathological grade II, out of them 37 were positive for

CD10 expression.Vandana Puri et al (2011) studied the expression of CD10 in 50 patients with breast carcinoma out of which 40 were positive and found that it correlated strongly with HER2neu and Ki67 positivity, ER/PR negativity and higher tumour grade .113

B.V. Anuradha Devi et al (2016) had studied the stromal CD 10 expression in 59 cases of breast cancer and found out significant relationship of CD 10 with increasing tumour size, increasing tumour grade, worsening prognosis and lymph node status.119. Thomas S. et al (2013) studied the effect of neo-adjuvant chemotherapy on stromal CD10 antigens in breast cancer. 29 patients scheduled for chemotherapy were studied, 16 had strong CD10 expression.

25%- CD10 Not correlating with H and E

75%- CD10 Correlating with H and E

Fig 1: Strong positive – CD10 in Invasive Breast Carcinoma patient (Grade 3) correlating with H and E

Strong CD10 positivity is significantly associated with lympho-vascular invasion in the patients.Lympho-vascular invasion is an independent prognostic marker which is associated with worse clinical outcome in breast cancer. Assessment of stromal CD10 positivity in core needle biopsy can supplement the grading of metastasis. Core needle biopsy should be an important part of preoperative work up and along with the traditional panel of markers, CD10 can put up routinely as a prognostic marker in all breast cancer patients.

Acknowledgements: None

Author’s contribution: Dr. Priyadarsini Tomughna - Study Concept, Data Analysis, Statistical Analysis, Literature Search, Manuscript Preparation and Editing. DrJadhav Priyanka - Study Concepts, Literature Search, Definition of intellectual content, Menu-script Preparation, Editing and Review. Dr Sahu Shilpi – Study Design, Menu-script Editing and Review.

Financial Support and Sponsorship: Nil

Conflicts of Interest: There are no conflicts of interest.

Data Availability: Data pertaining to this manuscript will be available on request.

1. Iwaya, H. Ogawa, M. Izumi, M. Kuroda, and K. Mukai, “Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome,” VirchowsArchiv, vol. 440, no. 6, pp. 589–593, 2002.
2. De Wever and M. Mareel, “Role of tissue stroma in cancer cell invasion,” Journal of Pathology, vol. 200, no. 4, pp. 429–447, 2003.
3. Johnson RH, Chien FL, Bleyer A. Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009. JAMA. 2013;309(8):800-805. doi:10.1001/jama.2013.776.
4. Ali HD, Jalal AJ, Ismai AT, Alnuaimy WMT. Stromal CD10 expression in invasive breast carcinoma. Zanco J Med Sci 2018;22:41‑8.
5. Ryu YJ, Kang SJ, Cho JS, Park MH. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy. Medicine (Baltimore) 2018;97:e11647.